Table 2.
Results of the REFLECT trial
| Lenvatinib (95% CI) (n = 478) | Sorafenib (95% CI) (n = 476) | Hazard ratio (95% CI) | |
|---|---|---|---|
| Median OS, months | 13.6 (12.1–14.9) | 12.3 (10.4–13.9) | 0.92 (0.79–1.06) |
| Median PFS, months* | 7.4 (6.9–8.8) | 3.7 (3.6–4.6) | 0.66 (0.57–0.77) |
| Median TTP, months* | 8.9 (7.4–9.2) | 3.7 (3.6–5.4) | 0.63 (0.53–0.73) |
| ORR, n (%)* | 115 (24) | 44 (9) | - |
OS, overall survival; PFS, progression-free survival; TTP, time to progression; ORR, overall response rate.
p < 0.0001.